Potential of bacteriophage therapy : a double edge sword to combat covid-19 and associated pulmonary bacterial infections
By: Bhargava, Kanika
.
Contributor(s): Nath, G.
Publisher: Mumbai Indian Journal of Pharmaceutical Science 2021Edition: Vol.83(6), Nov-Dec.Description: 1081-1093p.Subject(s): PHARMACEUTICSOnline resources: Click here
In:
Indian journal of pharmaceutical sciencesSummary: The Coronavirus Disease 2019 pandemic has wreaked havoc on global health infrastructure and personnel,
resulting in enormous misery, deaths and economic stagnation. Severe Acute Respiratory Syndrome-
Coronavirus-2 respiratory infections are frequently worsened by secondary bacterial infections and
co-infections due to prolonged hospitalizations; resulting in irreversible lung damage, respiratory failure,
cardiac arrest and death. The high mortality rate of Coronavirus Disease 2019 patients is primarily due
to multi drug resistant microbial (viral/bacterial) infections, unrestrained inflammatory response and
delayed antibody production. The superfluous use of broad spectrum antimicrobial drugs as the last resort
has further aggravated the Coronavirus Disease 2019 crisis by contributing to the global antimicrobial
resistance. To overcome these hurdles for effective treatment of Coronavirus Disease 2019 and associated
bacterial infections, phage therapy seems to be promising due to a lack of effective antiviral drugs and
antimicrobial-resistant superadded bacterial infections. Prior studies suggest that when phages, their
cocktails and endolysins are administered alone or in synergism with antibiotics through nebulization
or through intravenous and intraperitoneal injections have exhibited greater antibacterial potential to
combat even Multidrug-Resistant pulmonary bacterial infections. Bacteriophages and phagicin have
also shown potent antiviral activity by triggering the production of antiviral cytokines. Many studies
have also indicated phage mediated antiviral immunity by lowering Nuclear Factor Kappa B activation
and reactive oxygen species production. Phage display technique can serve as a promising approach
for Coronavirus Disease 2019 vaccine development through production of Severe Acute Respiratory
Syndrome-Coronavirus-2 specific antibodies. This review illustrates the potential of phage therapy as a
double edged sword to combat both Coronavirus Disease 2019 as well as associated bacterial infections.
| Item type | Current location | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|
Articles Abstract Database
|
School of Pharmacy Archieval Section | Not for loan | 2022-1217 |
The Coronavirus Disease 2019 pandemic has wreaked havoc on global health infrastructure and personnel,
resulting in enormous misery, deaths and economic stagnation. Severe Acute Respiratory Syndrome-
Coronavirus-2 respiratory infections are frequently worsened by secondary bacterial infections and
co-infections due to prolonged hospitalizations; resulting in irreversible lung damage, respiratory failure,
cardiac arrest and death. The high mortality rate of Coronavirus Disease 2019 patients is primarily due
to multi drug resistant microbial (viral/bacterial) infections, unrestrained inflammatory response and
delayed antibody production. The superfluous use of broad spectrum antimicrobial drugs as the last resort
has further aggravated the Coronavirus Disease 2019 crisis by contributing to the global antimicrobial
resistance. To overcome these hurdles for effective treatment of Coronavirus Disease 2019 and associated
bacterial infections, phage therapy seems to be promising due to a lack of effective antiviral drugs and
antimicrobial-resistant superadded bacterial infections. Prior studies suggest that when phages, their
cocktails and endolysins are administered alone or in synergism with antibiotics through nebulization
or through intravenous and intraperitoneal injections have exhibited greater antibacterial potential to
combat even Multidrug-Resistant pulmonary bacterial infections. Bacteriophages and phagicin have
also shown potent antiviral activity by triggering the production of antiviral cytokines. Many studies
have also indicated phage mediated antiviral immunity by lowering Nuclear Factor Kappa B activation
and reactive oxygen species production. Phage display technique can serve as a promising approach
for Coronavirus Disease 2019 vaccine development through production of Severe Acute Respiratory
Syndrome-Coronavirus-2 specific antibodies. This review illustrates the potential of phage therapy as a
double edged sword to combat both Coronavirus Disease 2019 as well as associated bacterial infections.
Click on an image to view it in the image viewer
There are no comments for this item.